Board of Directors
Michel de Rosen
Chairman of the Board of Directors
Chairman of Eutelsat Communications. Board member of Hispasat and ABB. More than 18 years experience in biotech and pharma companies. Former Chairman and CEO of Pharmuka, Rhône-Poulenc Rorer (now Sanofi), ViroPharma (now Shire), Saint-Gobain Desjonquières (now SGD). “Inspection Générale des Finances” (1976-80 and 1981-82), Chief of Staff of the Minister of Industry (1986-1988). Graduated from HEC Paris and the “Ecole Nationale d’Administration” (ENA).
Director, Chief Executive Officer
More than 30 years experience in academia, biotech and big pharma companies. Professor of Medical Genetics, founder of modern genetics, genomics and pharmacogenomics. Former CSO of Genset (acquired by Serono) and VP Genetics Worldwide of Serono Genetics Institute. Co-founder of Millennium Pharma, Genethon and the CEPH research institute. Author of 150 peer-reviewed publications.
Co-founder and General Partner of Truffle Capital. Leading investor in biotech/medtech in France and US. Founder and Chairman of Deinove and Abivax, co-founder and Board member of Carbios, Carmat, Biokinésis, Pharnext and Vexim, Board member of Myopowers, Kephalios, Symetis, Theraclion, Theradiag, Altimmune and Innate Pharma, founder of SangStat (Genzyme) and Conjuchem. Former Chairman of France Biotech, conceived the Young Innovative Entreprise Status (JEI), ex-Vice Chairman of Europabio. Inventor of 29 patents.
More than 25 years in senior executive positions at major international business groups such as Schlumberger, Schneider Electric, Valeo and Thomson. Former President and CEO of Converteam Group, acquired from Alstom, he developed and sold to General Electric after the value increased by 30. His fund ZAKA has especially invested in several biotechnology companies including Carmat and Cellectis of which he is Board member.
International lawyer in August & Debouzy. PhD in Economy, graduated from the “Ecole Nationale d’Administration” (ENA). MP and general rapporteur of the budget in the National Assembly, Member of the Supervisory Board of deposit and Consignment Office, Deputy Chairman of the Accor Group, State Secretary to the Minister of the Economy, Finance and Industry. Founder of funds SADEPAR, Board member of Deinove, Abivax and Pharnext.
Venture capital investor for more than 22 years in the US, primarily focused on biopharmaceutical and digital health companies. He led the creation of New Leaf Venture Partners as a spin-off from the Sprout Group and served on numerous boards of private and public healthcare companies such as Auxilium Pharmaceuticals (acquired by Endo), ePocrates Inc. (acquired by AthenaHealth), Truveris, NxStage Medical (acquisition by Fresenius Medical Care pending).
Former Vice-President R&D at Procter & Gamble. Member of the Board for Altria, Givaudan, BiOWiSH (Chair), Celltex, Deinove and Pharnext. Advisory Professor at Tsinghua University, Beijing. IRI Medalist, Holland Maurice award, P&G Alumni Innovation award. Author of several scientific and innovation management publications and co-inventor of more than 27 patents.